Credit Suisse’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Credit Suisse’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$763K	Sell	48,438 -479	-1%	-$6.59K	﹤0.01%	2428
2023 Q4	$741K	Sell	48,917 -1,391	-3%	-$20.3K	﹤0.01%	2532
2023 Q3	$1.01M	Sell	50,308 -9,505	-16%	-$241K	﹤0.01%	2299
2023 Q2	$1.69M	Buy	59,813 +22,444	+60%	+$538K	﹤0.01%	2034
2023 Q1	$643K	Buy	37,369 +12	+0%	+$243	﹤0.01%	2601
2022 Q4	$752K	Sell	37,357 -375	-1%	-$8.06K	﹤0.01%	2538
2022 Q3	$818K	Buy	37,732 +2,339	+7%	+$64K	﹤0.01%	2466
2022 Q2	$995K	Buy	35,393 +15,764	+80%	+$418K	﹤0.01%	2388
2022 Q1	$905K	Buy	19,629 +2,278	+13%	+$123K	﹤0.01%	2602
2021 Q4	$1.46M	Buy	17,351 +4,953	+40%	+$383K	﹤0.01%	3029
2021 Q3	$827K	Buy	12,398 +163	+1%	+$9.4K	﹤0.01%	3474
2021 Q2	$652K	Sell	12,235 -730	-6%	-$39.1K	﹤0.01%	3670
2021 Q1	$563K	Sell	12,965 -18,409	-59%	-$793K	﹤0.01%	3693
2020 Q4	$1.63M	Buy	+31,374	New	+$1.42M	﹤0.01%	2980

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Credit Suisse's ZNTL Position: Q1 2024 in Review

Credit Suisse reduced its Zentalis Pharmaceuticals (ZNTL) stake by 0.98% in Q1 2024, selling an estimated $6.59K and leaving 48,438 shares worth $763K. The position accounts for ﹤0.01% of the portfolio, ranked #2428.

Credit Suisse first reported a position in ZNTL in Q4 2020 and has held it in 14 quarters since. The position peaked at $1.69M in Q2 2023. 142 funds tracked by Wall St. Rank hold ZNTL as of Q1 2024.

Credit Suisse held 48,438 shares of Zentalis Pharmaceuticals worth $763K as of Q1 2024.
Credit Suisse sold 479 Zentalis Pharmaceuticals shares in Q1 2024, an estimated $6.59K.
Zentalis Pharmaceuticals made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2428 holding.
Credit Suisse first reported a position in Zentalis Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
Credit Suisse's Zentalis Pharmaceuticals position peaked at $1.69M in Q2 2023.
142 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.